Kunal C. Kadakia

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Randomized controlled trial of acitretin versus placebo in patients at high‐risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)

Kunal C. Kadakia, Debra L. Barton, Charles L. Loprinzi et al. · Cancer · 2011 · 85 citations · Full text

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

Kunal C. Kadakia, Claire Snyder, Kelley M. Kidwell et al. · The Oncologist · 2016 · 74 citations · Full text

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy

Alexis D. Leal, Kunal C. Kadakia, Sherry Looker et al. · Supportive Care in Cancer · 2014 · 49 citations · Full text

Fosaprepitant-induced Phlebitis, Medicine, Clinical Pharmacology +4

Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer

Mohamed E. Salem, Alberto Puccini, Sally J. Trufan et al. · The Oncologist · 2021 · 45 citations · Full text